STDY STEADYMED LTD

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQ: STDY) concerning possible violations of federal securities laws.

On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for its product candidate Treyvent. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. To obtain additional information, go to:

http://www.zlkdocs.com/STDY-Info-Request-Form-6069

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
31/08/2017

Underlying

STDYSTEADYMED LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STEADYMED LTD

 PRESS RELEASE
Free
STDY STEADYMED LTD

SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Fi...

SteadyMed Provides Corporate Update and Reports Second Quarter 2018 Financial Results SAN RAMON, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2018. Summary Corporate Update: On July 31, 2018, SteadyMed announced that its shareholders voted to approve the previously announced acquisition of...

August 14, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

SteadyMed Shareholders Approve Proposed Acquisition by United Therapeu...

SteadyMed Shareholders Approve Proposed Acquisition by United Therapeutics SAN RAMON, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that SteadyMed shareholders voted to approve the previously announced acquisition of the company by United Therapeutics Corporation (NASDAQ: UTHR) at an extraordinary general meeting of shareholders held on July 30, 2018. SteadyMed shareholders also app...

July 31, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisiti...

HSR Act Waiting Period Terminated for United Therapeutics’ Acquisition of SteadyMed Ltd. SILVER SPRING, Md. and SAN RAMON, Calif., July 20, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (NASDAQ:UTHR) and SteadyMed Ltd. (NASDAQ:STDY) announced today the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) relating to United Therapeutics’ previously announced acquisition of SteadyMed. As previously announced on April 30, 2018, United Therapeutics and SteadyMed entered into a definitive merger agreement under which Unite...

July 20, 2018 1 EN
STDY STEADYMED LTD

2 directors sold

Two Directors at Steadymed Ltd sold 56,567 shares at 4.500USD. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

07/04/18 July 4, 2018 1 EN
 PRESS RELEASE
Free
STDY STEADYMED LTD

The Law Offices of Vincent Wong Notifies Investors of an Investigation...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (NASDAQGM: STDY) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to United Therapeutics Corporation. Under the terms of the deal, SteadyMed stockholders will receive $4.46 per share in cash, with an additional $2.63 per share in cash upon achievement of a certain milestone related to SteadyMed’s Trevyent drug-device com...

May 7, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch